Dan Mellström
A5047826903- Bone health and osteoporosis research
- Hip and Femur Fractures
- Bone health and treatments
- Vitamin D Research Studies
- Nutrition and Health in Aging
- Bone Metabolism and Diseases
- Hormonal and reproductive studies
- Bone and Joint Diseases
- Body Composition Measurement Techniques
- Genetic Associations and Epidemiology
- Parathyroid Disorders and Treatments
- Estrogen and related hormone effects
- Nutrition, Genetics, and Disease
- Bone fractures and treatments
- Sexual Differentiation and Disorders
- Adipokines, Inflammation, and Metabolic Diseases
- Growth Hormone and Insulin-like Growth Factors
- Hip disorders and treatments
- Pelvic floor disorders treatments
- Liver Disease Diagnosis and Treatment
- Balance, Gait, and Falls Prevention
- Inflammatory Bowel Disease
- Cerebral Palsy and Movement Disorders
- Microscopic Colitis
- Musculoskeletal pain and rehabilitation
University of Gothenburg
2016-2025
Sahlgrenska University Hospital
2014-2025
National Academy of Medicine
2009-2024
Region Västra Götaland
2019-2021
Advisory Board Company (United States)
2021
CHR Verviers
2021
Karolinska Institutet
2010-2016
Centre for Family Medicine
2016
Skaraborg Hospital
2016
Washington University in St. Louis
2010
Once-daily injections of parathyroid hormone or its amino-terminal fragments increase bone formation and mass without causing hypercalcemia, but their effects on fractures are unknown.
The osteoblast-derived protein osteocalcin has recently been shown to affect adiposity and glucose homeostasis in mice, suggesting that the skeleton influences energy metabolism through an endocrine mechanism. aim of this study was investigate relationship between plasma parameters reflecting fat mass humans. Fasting levels osteocalcin, glucose, serum insulin, lipids were analyzed elderly men (75.3 +/- 3.2 yr age) Gothenburg part (all subjects, n = 1010; nondiabetic, 857; diabetic, 153) MrOS...
Abstract The 3-year FREEDOM trial assessed the efficacy and safety of 60 mg denosumab every 6 months for treatment postmenopausal women with osteoporosis. Participants who completed were eligible to enter an extension continue evaluation up 10 years. For results presented here, from group had 2 more years (long-term group) those placebo exposure (cross-over group). We report bone turnover markers (BTMs), mineral density (BMD), fracture rates, safety. A total 4550 enrolled in (2343 long-term;...
Abstract The role of androgens for bone health in elderly men is unclear. We show that free testosterone within the normal range a predictor BMD at predominantly cortical sites and previous osteoporosis-related fractures Swedish men. Introduction: Osteoporosis-related constitute major concern not only women but also Previous studies have clearly shown serum levels estradiol are associated with BMD, whereas more conflicting data been presented regarding predictive value (T) aim this study was...
The Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) extension is evaluating the long-term efficacy and safety denosumab for up to 10 years.The objective study was report results from first 3 years extension, representing exposure.This a multicenter, international, open-label 4550 women.Women FREEDOM group received more total (long-term) women placebo (crossover).Bone turnover markers (BTMs), bone mineral density (BMD), fracture, data are...